Analyst Price Target is $6.50
▲ +357.75% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Qualigen Therapeutics in the last 3 months. The average price target is $6.50, with a high forecast of $6.50 and a low forecast of $6.50. The average price target represents a 357.75% upside from the last price of $1.42.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Qualigen Therapeutics.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.